Achelous Partners Research
Advisory Approach
Achelous Partners is a pure-play life sciences M&A advisory firm with 25+ years of specialized experience. The firm operates with a singular focus: advising global life science and healthcare companies on mergers, acquisitions, and strategic transactions. Their thesis is that deep sector expertise—combined with genuine operational understanding of the life sciences industry—delivers superior outcomes for sellers. Unlike generalist investment banks that dabble in healthcare, Achelous has built its entire practice around the life sciences ecosystem, from pharma services and diagnostics to medical devices and research tools.
The firm's sweet spot is founder-owned and entrepreneur-led businesses in the $10M-$500M enterprise value range, particularly companies with complex technical offerings that require sophisticated buyers who understand the underlying science. Achelous maintains that relationships with life science-focused private equity firms and strategic buyers—who understand the long development cycles, regulatory pathways, and technical nuances of the sector—are more valuable than broad distribution to generalist buyers.
Achelous is not a fit for: (1) businesses below $10M TEV, (2) companies outside the life sciences/healthcare sectors, (3) founders seeking a limited or auction process, or (4) situations requiring public equity raise or debt financing (they focus exclusively on M&A advisory).
Sector Focus
Achelous' practice is organized around three core life science verticals:
Pharma, Biotech and Medtech Services: Contract research organizations (CROs), contract development and manufacturing organizations (CDMOs), bioanalytical testing laboratories, regulatory affairs consulting, medical affairs and medical communications, and market access/health economics outcomes research (HEOR) providers. The firm has particular depth in clinical trial services—central laboratories, niche CROs, and specialized service providers.
Diagnostics, Research Tools and Reagents: In vitro diagnostics (IVD) manufacturers, drug discovery tools and platforms, assay kits, bioinformatics and systems biology companies, separations and purification systems, and benchtop instruments. This includes reagent manufacturers, biological raw materials suppliers, and research consumables providers.
Healthcare: Medical technology companies, diagnostic/pathology service providers, professional and consumer health products, infection control and sterilization services, dental and veterinary health businesses, nutraceuticals/OTC products, and medical supply companies.
Deal Track Record
Achelous has completed 60+ transactions across 20+ years, with deep experience in cross-border deals involving US and European life science companies. Recent representative transactions include:
- Purna Pharmaceuticals to Ampersand Capital Partners (Feb 2026): Belgian contract development and manufacturing services provider for liquid and semi-solid dosage forms
- Plasma Services Group to Fujirebio (Jun 2025): New Jersey-based supplier of rare biological materials and samples for IVD and life science industries
- Curia US CDMO site to Siegfried (Jun 2024): Sale of early-phase pharmaceutical development and manufacturing facility
- A4P Consulting to LabConnect (Apr 2024): UK-based scientific consultancy for clinical trials acquired by global central laboratory services provider
- Six Degrees Worldwide to Reverba (Apr 2024): Medical communications agency acquired by patient engagement platform
- Symbio and Proinnovera to Archimed (Nov 2023): Dual sale of US and German consulting/testing firms to healthcare private equity specialist
- Bio X Cell to Windjammer Capital (Dec 2023): Leading producer of monoclonal antibodies for pre-clinical research
- Cergentis to Solvias (Jul 2022): Genomics-focused biotechnology company acquired to bolster cell and gene therapy capabilities
- Expression Systems to ANGUS Chemical (Nov 2022): Cell culture media and biological buffers manufacturer acquired by portfolio company of Ardian and Golden Gate Capital
- Clinical Outcomes Solutions to Validant (May 2021): Global leader in clinical outcomes assessment research services
- Diamond Pharma Services to ProPharma Group (Mar 2021): Pharmaceutical quality and compliance consulting acquired by portfolio company of Odyssey Investment Partners
- BioControl Systems to Merck/MilliporeSigma (2017): Food safety testing products company
- MLM Medical Labs to Great Point Partners (Dec 2019): German central laboratory for clinical trials
- BresMed Health Solutions to Arsenal Capital Partners (Feb 2020): Health economics and outcomes research consultancy
Process & Fee Structure
Achelous runs institutional-quality, targeted sell-side processes. The firm emphasizes that the breadth and quality of buyer outreach matters more than the number of buyers contacted. Typical engagement structure:
- Retainer: Monthly retainer required, credited against success fee
- Success fee: Industry-standard percentage tied to transaction value (typically 3-6% depending on deal size)
- Process timeline: 6-12 months from engagement to close, reflecting the technical complexity and due diligence requirements of life science assets
- Geographic scope: Achelous has completed transactions across North America, Europe, and cross-border deals spanning both regions
The firm requires exclusivity and focuses on one-on-one and targeted processes rather than broad auctions. The team provides comprehensive support including preparation of marketing materials, buyer identification and outreach, management presentation preparation, due diligence coordination, and transaction negotiation.
Buyer Network
Achelous has built deep relationships with life science-focused private equity firms globally, including: Archimed (Belgium), Ampersand Capital Partners (US/Netherlands), Windjammer Capital (US), Arsenal Capital Partners (US), Great Point Partners (US), 424 Capital (UK), and Ardian (France), as well as strategic buyers like Fujirebio (Japan), Solvias (Switzerland), Merck/MilliporeSigma (Germany), and ANGUS Chemical (US).
The firm's European representatives—based in Sweden, Germany, and the Netherlands—provide direct access to European strategic and financial buyers. This transatlantic network is a key differentiator, as many life science businesses have natural buyer pools on both continents.
Competitive Positioning
Achelous differentiates through:
- Pure-play specialization: 100% of transactions are in life sciences and healthcare
- Operational credibility: Team members include former life science operators (former EVP/COO of AddLife AB, former CEOs of diagnostic and CRO companies)
- Transatlantic reach: US-based partners with European representatives who are native to the markets they cover
- Technical understanding: The team understands the science underlying their clients' businesses, enabling more effective buyer communication
- Long-term relationships: 25+ years of sector focus means they know the buyers, have completed repeat transactions with many PE firms, and understand the strategic priorities of both financial and strategic acquirers
Team
Achelous' team combines investment banking experience with deep life sciences expertise:
- Mark R. Saunders, President: Leading investment banker to international public and private life science companies; former head of Greenberg Traurig's International Corporate Finance Group; extensive experience in cross-border M&A and US listings for non-US companies
- Marius Sava, Managing Director (Los Angeles): 20+ years of M&A experience; over $1 billion in transaction value; advised clients including Ansell, Covance, Life Technologies, Novozymes
- Eric L. Zitter, Managing Director (New York): Focuses on deal origination and cross-border M&A; former Business Development Analyst at Quintiles Transnational; bioengineering background
- Akshay Nadkarni, Managing Director (New York): Has led transactions valued at $3.0+ billion involving 50+ companies; extensive experience with life science tools, reagents, diagnostics, and specialty pharma; worked with IQVIA, Catalent, Eurofins, Lonza, Merck KGaA, Tecan, Danaher, ThermoFisher
- Barbara Lu, Vice President: CFA charterholder; 10+ years of investment banking experience; international background across US, France, and China; expertise in outsourced life sciences services
- Charles P. Tebbetts, Vice President: Has led buy-side, sell-side, and cross-border engagements since 2014; sector expert in life science outsourced services, IVD diagnostics, and medtech
- Artur Aira, European Representative (Sweden): Former Executive Vice President and COO of AddLife AB; led Nordic diagnostics and biomedical research company to 600+ employees and $250M+ sales; completed successful IPO in 2016
- Dr. Jan Boesen, European Representative (The Netherlands): 20+ years life sciences industry experience; former CEO of Amsterdam Molecular Therapeutics (now UniQure); during his tenure, Glybera became the first gene therapy approved by European Commission
- Dr. Katja Neuer, European Representative (Germany): Chemist by training; former Director at MLM Medical Labs where she grew the company from 20 to 80+ employees
- Prof. Dr. Med. Klaus-Peter Wilhelm, European Representative (Germany): Former CEO and founder of proderm, a leading dermatology CRO with 100+ employees
- Dr. Stephan Wnendt, European Representative (Germany): Almost 30 years of experience in life sciences; former CEO of Kourion Therapeutics; led merger with ViaCell and subsequent NASDAQ IPO
Geographic Coverage
Primary presence in New York City with managing directors in Los Angeles and European representatives covering Sweden, Germany, and the Netherlands. The firm has completed transactions across the United States and Europe, with particular depth in cross-border deals between these regions. Many transactions involve companies with multinational operations or buyers from different continents than the sellers.